FDA — authorised 21 December 2012
- Marketing authorisation holder: AEGERION
- Status: approved
🇺🇸 Juxtapid in United States
FDA authorised Juxtapid on 21 December 2012
Marketing authorisations
FDA — authorised 21 December 2012
- Application: NDA203858
- Marketing authorisation holder: CHIESI
- Local brand name: JUXTAPID
- Indication: CAPSULE — ORAL
- Status: approved
Juxtapid in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Juxtapid approved in United States?
Yes. FDA authorised it on 21 December 2012; FDA authorised it on 21 December 2012.
Who is the marketing authorisation holder for Juxtapid in United States?
AEGERION holds the US marketing authorisation.